Filo Mining Corp News - FIL

Bristol Myers Squibb Reports Second Quarter Financial Results for 2024

Results Underscore Continued Progress on Commercial Execution, Driving the Growth Portfolio and Pipeline Advancement Second Quarter Revenues were...

U.S. Index Futures Point to Higher Open, Oil Prices Down

U.S. index futures point to a higher open in pre-market trading on Friday, with investors preparing for the...

Dexcom Shares Drop 37% on Weak Revenue and Forecast; Coursera Rises 24% After Beating Q2 Revenue Estimates

Dexcom (NASDAQ:DXCM) – The continuous glucose monitor company reported second-quarter revenue of $1...

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

The Application is based on Phase 3 CheckMate -9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to...

Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in Virtual Targeted Protein Degradation Day hosted by UBS...

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Approval based on results from the Phase 1/2 KRYSTAL-1 study where KRAZATI in combination with cetuximab showed an objective response rate of 34...

European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab

Validation is based on results from CheckMate -67T, the first Phase 3 trial of the subcutaneous formulation of Opdivo to evaluate and demonstrate...

Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024

Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2024 on Friday, July 26, 2024. Company executives will review...

Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board...

Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty cents ($0.60) per share...

U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid...

Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial

Late-breaking data to be presented at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting Dual immunotherapy combination of...

Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference...

Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting

Three-year follow-up results from TRANSFORM show ongoing event-free survival and durable responses with Breyanzi compared to standard of care...

Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer

Late-breaking exploratory analysis of the CheckMate -77T study of perioperative Opdivo shows improved event-free survival and pathologic complete...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Filo Mining Corp (FIL)

Professional-Grade Tools, for Individual Investors.

FIL News

Bristol Myers Squibb Reports Second Quarter Financial Results for 2024

U.S. Index Futures Point to Higher Open, Oil Prices Down

Dexcom Shares Drop 37% on Weak Revenue and Forecast; Coursera Rises 24% After Beating Q2 Revenue Estimates

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab

Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024

Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors

Bristol Myers Squibb Announces Dividend

U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial

Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting

Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer

FIL Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Filo Mining Corp (FIL) News

Filo Mining Corp (FIL)

Professional-Grade Tools, for Individual Investors.

FIL News

Bristol Myers Squibb Reports Second Quarter Financial Results for 2024

U.S. Index Futures Point to Higher Open, Oil Prices Down

Dexcom Shares Drop 37% on Weak Revenue and Forecast; Coursera Rises 24% After Beating Q2 Revenue Estimates

Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma

Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day

Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab

Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024

Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors

Bristol Myers Squibb Announces Dividend

U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial

Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting

Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer

FIL Discussion

Your Recent History